Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -395.25% is 22% below its 5-year average of -323.85%, around the middle of its 5-year range (-663.22%–27.32%).
18.86% below its 12-month average of -332.55%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -391.64%.
NET PROFIT MARGIN
-395.25%
NET PROFIT MARGIN AVG TTM
-332.55%
NET PROFIT MARGIN AVG 3Y
-371.39%
NET PROFIT MARGIN AVG 5Y
-323.85%
NET PROFIT MARGIN AVG 10Y
-238.89%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-18.86%
CURRENT VS 3Y AVG
-6.42%
CURRENT VS 5Y AVG
-22.05%
CURRENT VS 10Y AVG
-65.45%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-112828.57%
vs the sector median at left
Sutro Biopharma, Inc.
Market Cap
$139.84M
Net Profit Margin
-395.25%
TTM Avg
-332.55%
3Y Avg
-371.39%
5Y Avg
-323.85%
Market Cap
$139.47M
Net Profit Margin
-153.61%
TTM Avg
-101.12%
3Y Avg
-50.56%
5Y Avg
-33.71%
Market Cap
$139.04M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-3984.32%
5Y Avg
-3047.80%
Market Cap
$137.80M
Net Profit Margin
-4.03%
TTM Avg
-12.22%
3Y Avg
-25.92%
5Y Avg
-21.35%
Market Cap
$136.67M
Net Profit Margin
-396.52%
TTM Avg
-411.88%
3Y Avg
-411.88%
5Y Avg
-411.88%
Market Cap
$143.10M
Net Profit Margin
-435.70%
TTM Avg
-1104.64%
3Y Avg
-1053.90%
5Y Avg
-4200.61%
Market Cap
$136.57M
Net Profit Margin
27.54%
TTM Avg
-18.99%
3Y Avg
-63.93%
5Y Avg
-73.34%
Market Cap
$143.60M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$143.84M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sutro Biopharma, Inc. (STRO) | $139.84M | -395.25% | -332.55% | -371.39% | -323.85% |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | -153.61% | -101.12% | -50.56% | -33.71% |
| Immuneering Corporation (IMRX)vs › | $139.04M | 0.00% | 0.00% | -3984.32% | -3047.80% |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.80M | -4.03% | -12.22% | -25.92% | -21.35% |
| Atrium Therapeutics, Inc. (RNA)vs › | $136.67M | -396.52% | -411.88% | -411.88% | -411.88% |
| Nyxoah S.A. (NYXH)vs › | $143.10M | -435.70% | -1104.64% | -1053.90% | -4200.61% |
| Organigram Global Inc. (OGI)vs › | $136.57M | 27.54% | -18.99% | -63.93% | -73.34% |
| Protara Therapeutics, Inc. (TARA)vs › | $143.60M | 0.00% | 0.00% | 0.00% | 0.00% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | 0.00% | 0.00% | 0.00% | 0.00% |
| Freenome, Inc. (FRNM)vs › | $133.45M | N/A | N/A | N/A | N/A |
Operating Margin
-102.4%
Net Profit Margin
-395.3%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -391.64% |
| 2026-03-31 | -264.99% |
| 2025-12-31 | -401.49% |
| 2025-09-30 | -586.58% |
| 2025-06-30 | -18.04% |
| 2025-03-31 | -436.62% |
| 2024-12-31 | -489.18% |
| 2024-09-30 | -572.62% |
| 2024-06-30 | -186.80% |
| 2024-03-31 | -447.52% |
| 2023-12-31 | 27.32% |
| 2023-09-30 | -291.21% |
| 2023-06-30 | -370.00% |
| 2023-03-31 | -394.90% |
| 2022-12-31 | -400.76% |
| 2022-09-30 | -77.50% |
| 2022-06-30 | -92.58% |
| 2022-03-31 | -663.22% |
| 2021-12-31 | -357.85% |
| 2021-09-30 | -362.83% |
| 2021-06-30 | -21.93% |
| 2021-03-31 | -207.09% |
| 2020-12-31 | -719.30% |
| 2020-09-30 | 96.16% |
| 2020-06-30 | 315.47% |
| 2020-03-31 | -273.98% |
| 2019-12-31 | -130.82% |
| 2019-09-30 | -105.17% |
| 2019-06-30 | -131.05% |
| 2019-03-31 | -165.14% |
| 2018-12-31 | -7.82% |
| 2018-09-30 | -130.64% |
| 2018-06-30 | -202.33% |
| 2018-03-31 | -207.94% |
| 2017-12-31 | -379.80% |
| 2017-09-30 | -8.10% |
| 2017-06-30 | -9.69% |
| 2017-03-31 | -9.69% |
